新西兰社区药师对补充药物不良反应报告的定性研究
本研究通过半结构化访谈27名新西兰社区药师,探讨其对补充药物(CMs)不良反应(ADRs)报告的看法与经验。结果显示药师虽认可报告重要性,但实际提交报告极少且未鼓励患者报告,障碍包括时间压力、因果不确定性、报告机制不熟悉及缺乏报酬。
要点
- 社区药师认可CMs的ADR报告重要性,但实际提交报告极少。
- 药师未主动鼓励患者/消费者报告CMs相关ADRs。
- 报告障碍包括时间压力、因果不确定性、机制不熟悉及无报酬。
核心结论
- 社区药师对CMs的ADR识别与报告多采取被动方式,虽认可其重要性但实际报告极少。
研究设计与样本
- 定性研究,采用深入半结构化访谈,对27名执业社区药师进行目的性和便利抽样,数据用一般归纳法分析。
主要发现
- 参与者熟悉ADR报告系统,认为CMs的ADR报告重要且药师应参与,但极少提交CMs的ADR报告,且无人鼓励患者/消费者报告。
- 参与者解释未报告原因是患者从未告知其CMs相关ADRs;会报告严重ADRs,但时间压力、因果不确定性、对CMs ADR报告机制缺乏了解及缺乏报酬是阻碍因素。
- 参与者了解处方药的强化监测研究,理解考虑用于CMs的理由,并认识到潜在实践困难。
临床怎么用
- 药师可利用CMs安全性知识减少消费者伤害风险,但需转向主动的药物警戒策略,尤其识别和报告ADRs,并赋能CMs使用者报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Detecting signals of safety concerns associated with complementary medicines (CMs) relies on spontaneous reports submitted by health professionals and patients/consumers. Community pharmacists are well placed to identify and report suspected adverse drug reactions (ADRs) associated with CMs, but pharmacists submit few CMs ADR reports. OBJECTIVES: The aim of this study was to explore New Zealand community pharmacists' views and experiences with ADR reporting for CMs. METHODS: Qualitative, in-depth, semi-structured interviews were undertaken with 27 practising community pharmacists identified through purposive and convenience sampling. Data were analysed using a general inductive approach. RESULTS: Participants were familiar with systems for reporting ADRs, believed ADR reporting for CMs important, and that pharmacists should contribute. However, few submitted reports of CMs ADRs and none encouraged patients/consumers to do so. Participants explained this was because they had never been informed by patients about ADRs associated with CMs. Participants said they would report serious ADRs; time pressures, lack of certainty around causality, lack of awareness of mechanisms for reporting CMs ADRs, and lack of remuneration were deterrents to reporting. Participants were aware of intensive-monitoring studies for prescription medicines, understood the rationale for considering this approach for CMs and recognised there would be potential practical difficulties. CONCLUSIONS: Participants used their knowledge of CMs safety concerns to minimise risk of harms to consumers from CMs use, but most had a passive approach to identifying and reporting ADRs for CMs. There is substantial potential for pharmacists to adopt proactive strategies in pharmacovigilance for CMs, particularly in recognising and reporting ADRs, and empowering CMs users to do the same.
引用
- Barnes J, Butler R. Community Pharmacists' Views and Experiences with ADR Reporting for Complementary Medicines: A Qualitative Study in New Zealand. Drug Saf. 2020. PMID: 32975740. doi:10.1007/s40264-020-00980-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。